Therapeutic angiogenesis in coronary artery disease: a review of mechanisms and current approaches

References

• Virani SS, Alvaro A, Benjamin EJ, et al. Heart disease and stroke statistics—2020 update: a report from the American heart association. Circulation. 2020 Mar 3;141(9):e139–596.
   PubMed Web of Science ®Google Scholar
• Corpataux N, Spirito A, Gragnano F, et al. Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk. Eur Heart J. 2020 Oct 7;41(38):3743–3749.
   PubMed Web of Science ®Google Scholar
• Ueki Y, Bär S, Losdat S, et al. Validation of the Academic Research Consortium for High Bleeding Risk (ARC-HBR) criteria in patients undergoing percutaneous coronary intervention and comparison with contemporary bleeding risk scores. EuroIntervention. 2020 Aug;16(5):371–379.
   PubMed Web of Science ®Google Scholar
• Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol. 2002 Dec;29(6 Suppl 16):10–14.
   PubMed Web of Science ®Google Scholar
• Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989 Jun 15;161(2):851–858.
   PubMed Web of Science ®Google Scholar
• Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med. 2000 Apr;6(4):389–395.
   PubMed Web of Science ®Google Scholar
• Risau W. Mechanisms of angiogenesis. Nature. 1997 Apr;386(6626):671–674.
   PubMed Web of Science ®Google Scholar
• Wolfgang S, Ito Wulf D. Molecular mechanisms of coronary collateral vessel growth. Circ Res. 1996 Nov 1;79(5):911–919.
   PubMed Web of Science ®Google Scholar
• Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011 Sep 16;146(6):873–887.
   PubMed Web of Science ®Google Scholar
• Yu AY, Shimoda LA, Iyer NV, et al. Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1α. J Clin Invest. 1999 Mar 1;103(5):691–696.
   PubMed Web of Science ®Google Scholar
• Buschmann I, Schaper W. Arteriogenesis versus angiogenesis: two mechanisms of vessel growth. News Physiol Sci Int J Physiol Prod Jointly Int Union Physiol Sci Am Physiol Soc. 1999 Jun;14:121–125.
   Google Scholar
• Schaper W. Collateral circulation. Basic Res Cardiol. 2009 Jan;104(1):5–21.
   PubMed Web of Science ®Google Scholar
• Zimarino M, D’Andreamatteo M, Waksman R, et al. The dynamics of the coronary collateral circulation. Nat Rev Cardiol. 2014 Apr;11(4):191–197.
   PubMed Web of Science ®Google Scholar
• Werner GS, Jandt E, Krack A, et al. Growth Factors in the collateral circulation of chronic total coronary occlusions: relation to duration of occlusion and collateral function. Circulation. 2004 Oct 5;110(14):1940–1945.
   PubMed Web of Science ®Google Scholar
• Segura I, Serrano A, Buitrago GGD, et al. Inhibition of programmed cell death impairs in vitro vascular-like structure formation and reduces in vivo angiogenesis. FASEB J. 2002;16(8):833–841.
   PubMed Web of Science ®Google Scholar
• Krysko DV, Vandenabeele P. From regulation of dying cell engulfment to development of anti-cancer therapy. Cell Death Differ. 2008 Jan;15(1):29–38.
   PubMed Web of Science ®Google Scholar
• Reinisch A, Bartmann C, Rohde E, et al. Humanized system to propagate cord blood-derived multipotent mesenchymal stromal cells for clinical application. Regen Med. 2007 Jul 1;2(4):371–382.
   PubMed Web of Science ®Google Scholar
• Hofmann NA, Reinisch A, Strunk D. Endothelial colony-forming progenitor cell isolation and expansion. In: Sr Seditor, Somatic stem cells: methods and protocols [internet]. Totowa, NJ:Humana Press;2012. cited 2021 Mar 28]. p. 381–387. (Methods in Molecular Biology)https://doi.org/10.1007/978-1-61779-815-3_23
   Google Scholar
• Tian X, Hu T, He L, et al. Peritruncal Coronary endothelial cells contribute to proximal coronary artery stems and their aortic orifices in the mouse heart. PLOS ONE. 2013 Nov 21;8(11):e80857.
   PubMed Web of Science ®Google Scholar
• Wu B, Zhang Z, Lui W, et al. Endocardial cells form the coronary arteries by angiogenesis through myocardial-endocardial VEGF signaling. Cell. 2012 Nov 21;151(5):1083–1096.
   PubMed Web of Science ®Google Scholar
• Majesky MW. Development of coronary vessels. In: Current topics in developmental biology [internet]. Academic Press; 2004. cited 2021 Mar 28. p. 225–259. ( Developmental Vascular Biology; 62). Available from. https://www.sciencedirect.com/science/article/pii/S0070215304620084
   Google Scholar
• Olivey HE, Svensson EC. Epicardial-Myocardial signaling directing coronary vasculogenesis. Circ Res. 2010Mar19;106(5):818–832.
   PubMed Web of Science ®Google Scholar
• Buschmann I, Heil M, Jost M, et al. Influence of inflammatory cytokines on arteriogenesis. Microcirculation. 2003;10(3–4):371–379.
   PubMed Web of Science ®Google Scholar
• Fraisl P, Mazzone M, Schmidt T, et al. Regulation of Angiogenesis by Oxygen and Metabolism. Dev Cell. 2009 Feb 17;16(2):167–179.
   PubMed Web of Science ®Google Scholar
• Nakada Y, Canseco DC, Thet S, et al. Hypoxia induces heart regeneration in adult mice. Nature. 2017 Jan;541(7636):222–227.
   PubMed Web of Science ®Google Scholar
• Bloor CM. Angiogenesis during exercise and training. Angiogenesis. 2005Dec1;8(3):263–271.
   PubMedGoogle Scholar
• Walton CB, Ecker J, Anderson CD, et al. Cardiac angiogenesis directed by stable hypoxia inducible factor-1. Vasc Cell. 2013 Aug 29;5(1):15.
   PubMedGoogle Scholar
• Song JW, Munn LL. Fluid forces control endothelial sprouting. Proc Natl Acad Sci U S A. 2011 Sep 13;108(37):15342–15347.
   PubMed Web of Science ®Google Scholar
• Galie PA, Nguyen D-HT, Choi CK, et al. Fluid shear stress threshold regulates angiogenic sprouting. Proc Natl Acad Sci U S A. 2014 Jun 3;111(22):7968–7973.
   PubMed Web of Science ®Google Scholar
• Vickerman V, Kamm RD. Mechanism of a flow-gated angiogenesis switch: early signaling events at cell-matrix and cell-cell junctions. Integr Biol Quant Biosci Nano Macro. 2012 Aug;4(8):863–874.
   Google Scholar
• Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev. 2000 Jun;52(2):237–268.
   PubMed Web of Science ®Google Scholar
• Maija B, Riikka K, Tanja H, et al. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation. 2010 Oct 26;122(17):1725–1733.
   PubMed Web of Science ®Google Scholar
• Kivelä R, Bry M, Robciuc MR, et al. VEGF-B-induced vascular growth leads to metabolic reprogramming and ischemia resistance in the heart. EMBO Mol Med. 2014 Mar;6(3):307–321.
   PubMed Web of Science ®Google Scholar
• Aydin HI, Yozgat Y, Demirkaya E, et al. Correlation between vascular endothelial growth factor and leptin in children with cyanotic congenital heart disease. Turk J Pediatr. 2007 Dec;49(4):360–364.
   PubMed Web of Science ®Google Scholar
• Ripa RS. Granulocyte-colony stimulating factor therapy to induce neovascularization in ischemic heart disease. Dan Med J. 2012 Mar;59(3):B4411.
   PubMed Web of Science ®Google Scholar
• Siervo M, Ruggiero D, Sorice R, et al. Angiogenesis and biomarkers of cardiovascular risk in adults with metabolic syndrome. J Intern Med. 2010;268(4):338–347.
   PubMed Web of Science ®Google Scholar
• Jaba IM, Zhuang ZW, Li N, et al. NO triggers RGS4 degradation to coordinate angiogenesis and cardiomyocyte growth. J Clin Invest. 2013 Apr 1;123(4):1718–1731.
   PubMed Web of Science ®Google Scholar
• Accornero F, van Berlo JH, Benard MJ, et al. Placental growth factor regulates cardiac adaptation and hypertrophy through a paracrine mechanism. Circ Res. Internet]. 2011 Jul 22 [cited 2021 Mar 28];109(3). 272–280.
   PubMed Web of Science ®Google Scholar
• House SL, Wang J, Castro AM, et al. Fibroblast growth factor 2 is an essential cardioprotective factor in a closed‐chest model of cardiac ischemia‐reperfusion injury. Physiol Rep Internet]. 2015 Jan 27; 3(1):e12278.
   Web of Science ®Google Scholar
• Kato J, Kitamura K. Bench-to-bedside pharmacology of adrenomedullin. Eur J Pharmacol. 2015 Oct 5;764:140–148.
   PubMed Web of Science ®Google Scholar
• Kimáková P, Solár P, Solárová Z, et al. Erythropoietin and Its Angiogenic Activity. Int J Mol Sci [Internet]. 2017 Jul 13 [ cited 2021 Mar 28];18(7). Available from:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5536009/
   PubMed Web of Science ®Google Scholar
• Visconti RP, Richardson CD, Sato TN. Orchestration of angiogenesis and arteriovenous contribution by angiopoietins and vascular endothelial growth factor (VEGF). Proc Natl Acad Sci U S A. 2002 Jun 11;99(12):8219–8224.
   PubMed Web of Science ®Google Scholar
• Sun L, Li W, Lei F, et al. The regulatory role of microRNAs in angiogenesis‐related diseases. J Cell Mol Med. 2018 Oct;22(10):4568–4587.
   PubMed Web of Science ®Google Scholar
• Toldo S, Das A, Mezzaroma E, et al. Induction of MicroRNA-21 with exogenous hydrogen sulfide attenuates myocardial ischemic and inflammatory injury in mice. Circ Cardiovasc Genet. 2014 Jun;7(3):311–320.
   PubMedGoogle Scholar
• Salloum FN. Hydrogen sulfide and cardioprotection — mechanistic insights and clinical translatability. Pharmacol Ther. 2015 Aug 1;152:11–17.
   PubMed Web of Science ®Google Scholar
• Gragnano F, Calabrò P. Role of dual lipid-lowering therapy in coronary atherosclerosis regression: evidence from recent studies. Atherosclerosis. 2018 Feb;269:219–228.
   PubMed Web of Science ®Google Scholar
• Parma L, Baganha F, Quax PHA, et al. Plaque angiogenesis and intraplaque hemorrhage in atherosclerosis. Eur J Pharmacol. 2017 Dec;5(816):107–115.
   Google Scholar
• Howangyin K-Y, Zlatanova I, Pinto C, et al. Myeloid-Epithelial-Reproductive receptor tyrosine kinase and milk fat globule epidermal growth factor 8 coordinately improve remodeling after myocardial infarction via local delivery of vascular endothelial growth factor. Circulation. 2016 Mar 1;133(9):826–839.
   PubMed Web of Science ®Google Scholar
• Wu X, Reboll MR, Korf-Klingebiel M, et al. Angiogenesis after acute myocardial infarction. Cardiovasc Res. Internet]. 2020 Oct 16 [cited 2021 Mar 28];(cvaa287). https://doi.org/10.1093/cvr/cvaa287.
   Google Scholar
• Seiler C, Stoller M, Pitt B, et al. The human coronary collateral circulation: development and clinical importance. Eur Heart J. 2013 Sep 7;34(34):2674–2682.
   PubMed Web of Science ®Google Scholar
• Das S, Goldstone AB, Wang H, et al. A unique collateral artery development program promotes neonatal heart regeneration. Cell. 2019 Feb 21;176(5):1128–1142.e18.
   PubMed Web of Science ®Google Scholar
• Mitsos S, Katsanos K, Koletsis E, et al. Therapeutic angiogenesis for myocardial ischemia revisited: basic biological concepts and focus on latest clinical trials. Angiogenesis. 2012 Mar 1;15(1):1–22.
   PubMed Web of Science ®Google Scholar
• Zhang R, Wang L, Zhang L, et al. Nitric oxide enhances angiogenesis via the synthesis of vascular endothelial growth factor and cGMP After stroke in the rat. Circ Res. 2003 Feb 21;92(3):308–313.
   PubMed Web of Science ®Google Scholar
• Inampudi C, Akintoye E, Ando T, et al. Angiogenesis in peripheral arterial disease. Curr Opin Pharmacol. 2018 Apr;39:60–67.
   PubMed Web of Science ®Google Scholar
• Gorenoi V, Brehm MU, Koch A, et al. Growth factors for angiogenesis in peripheral arterial disease. Cochrane vascular group, editor. Cochrane Database Syst Rev [Internet]. 2017Jun8; https://doi.org/10.1002/14651858.CD011741.pub2.
   Google Scholar
• Harada K, Friedman M, Lopez JJ, et al. Vascular endothelial growth factor administration in chronic myocardial ischemia. Am J Physiol. 1996 May;270(5 Pt 2):H1791–1802.
   PubMedGoogle Scholar
• Lopez JJ, Laham J, Stamler R, et al. A. VEGF administration in chronic myocardial ischemia in pigs. Cardiovasc Res. 1998Nov1;40(2):272–281
   PubMed Web of Science ®Google Scholar
• Banai S, Jaklitsch MT, Shou M, et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation. 1994 May 1;89(5):2183–2189.
   PubMed Web of Science ®Google Scholar
• Pearlman JD, Hibberd MG, Chuang ML, et al. Magnetic resonance mapping demonstrates benefits of VEGF–induced myocardial angiogenesis. Nat Med. 1995 Oct;1(10):1085–1089.
   PubMed Web of Science ®Google Scholar
• Hariawala MD, Horowitz JR, Esakof D, et al. VEGF improves myocardial blood flow but produces edrf-mediated hypotension in porcine hearts. J Surg Res. 1996 Jun 1;63(1):77–82.
   PubMed Web of Science ®Google Scholar
• Voisine P, Bianchi C, Ruel M, et al. Inhibition of the cardiac angiogenic response to exogenous vascular endothelial growth factor. Surgery. 2004 Aug 1;136(2):407–415.
   PubMed Web of Science ®Google Scholar
• Munir B, Sodha NR, Shigetoshi M, et al. Functional, cellular, and molecular characterization of the angiogenic response to chronic myocardial Ischemia in diabetes. Circulation. 2007 Sep 11;116(11_supplement):I–31.
   Web of Science ®Google Scholar
• Symes JF, Losordo DW, Vale PR, et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann Thorac Surg. 1999 Sep 1;68(3):830–836.
   PubMed Web of Science ®Google Scholar
• Rosengart Todd K, Lee Leonard Y, Patel Shailen R, et al. Angiogenesis gene therapy. Circulation. 1999 Aug 3;100(5):468–474.
   PubMedGoogle Scholar
• Henry TD, Annex BH, McKendall George R, et al. The VIVA Trial. Circulation. 2003 Mar 18;107(10):1359–1365.
   PubMed Web of Science ®Google Scholar
• Hedman M, Hartikainen J, Syvänne M, et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation. 2003 Jun 3;107(21):2677–2683.
   PubMed Web of Science ®Google Scholar
• Ylä-Herttuala S, Martin JF. Cardiovascular gene therapy. Lancet. 2000 Jan 15;355(9199):213–222.
   PubMed Web of Science ®Google Scholar
• Losordo Douglas W, Vale Peter R, Symes James F, et al. Gene therapy for myocardial angiogenesis. Circulation. 1998 Dec 22;98(25):2800–2804.
   PubMedGoogle Scholar
• Nabel EG, Plautz G, Nabel GJ. Site-Specific gene expression in vivo by direct gene transfer into the arterial wall. Science. 1990 Sep 14;249(4974):1285.
   PubMed Web of Science ®Google Scholar
• Vale Peter R, Losordo Douglas W, Milliken Charles E, et al. Randomized, Single-Blind, Placebo-Controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial Ischemia. Circulation. 2001 May 1;103(17):2138–2143.
   PubMed Web of Science ®Google Scholar
• Losordo DW, Vale PR, Hendel RC, et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation. 2002 Apr 30;105(17):2012–2018. 10.1161/01.CIR.0000015982.70785.B7.
   PubMed Web of Science ®Google Scholar
• Jeong G-J, Oh JY, Kim Y-J, et al. Therapeutic angiogenesis via solar cell-facilitated electrical stimulation. ACS Appl Mater Interfaces. 2017 Nov 8;9(44):38344–38355.
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Hilton JD, Arnold JMO, et al. Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF 121 (AdVEGF121) versus maximum medical treatment. Gene Ther. 2006 Nov;13(21):1503–1511. 10.1038/sj.gt.3302802.
   PubMed Web of Science ®Google Scholar
• Stewart DJ, Kutryk MJB, Fitchett D, et al. VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. Mol Ther J Am Soc Gene Ther. 2009 Jun;17(6):1109–1115. 10.1038/mt.2009.70.
   PubMed Web of Science ®Google Scholar
• Harada K, Grossman W, Friedman M, et al. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts. J Clin Invest. 1994 Aug 1;94(2):623–630.
   PubMed Web of Science ®Google Scholar
• Yanagisawa-Miwa A, Uchida Y, Nakamura F. Salvage of infarcted myocardium by angiogenic action of basi. Science. 1992 Sep 4;257(5075):1401.
   PubMed Web of Science ®Google Scholar
• Baffour R, Berman J, Garb JL, et al. Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: dose-response effect of basic fibroblast growth factor. J Vasc Surg. 1992 Aug 1;16(2):181–191.
   PubMed Web of Science ®Google Scholar
• Cuevas P, Giménez-Gallego G, Carceller F. Single topical application of human recombinant basic fibroblast growth factor (rbfgf) promotes neovascularization in rat cerebral cortex. Surg Neurol. 1993 May 1;39(5):380–384.
   PubMedGoogle Scholar
• Schumacher B, Pecher P, von Specht BU, et al. Induction of neoangiogenesis in Ischemic myocardium by human growth factors. Circulation. 1998Feb24;97(7):645–650.
   PubMed Web of Science ®Google Scholar
• Ruel M, Laham RJ, Parker JA, et al. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J Thorac Cardiovasc Surg. 2002 Jul 1;124(1):28–34.
   PubMed Web of Science ®Google Scholar
• Michael S, Annex BH, Laham RJ, et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2. Circulation. 2002 Feb 19;105(7):788–793.
   PubMed Web of Science ®Google Scholar
• Giordano FJ, Ping P, McKirnan MD, et al. Intracoronary gene transfer of fibroblast growth factor–5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med. 1996 May;2(5):534–539.
   PubMed Web of Science ®Google Scholar
• Grines CL, Watkins MW, Helmer G, et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation. 2002 Mar 19;105(11):1291–1297. 10.1161/hc1102.105595.
   PubMed Web of Science ®Google Scholar
• Grines CL, Watkins MW, Mahmarian JJ, et al. A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. J Am Coll Cardiol. 2003 Oct;42(8):1339–1347. 10.1016/S0735-1097(03)00988-4.
   PubMed Web of Science ®Google Scholar
• Td H, Cl G, Watkins MW, et al. Effects of Ad5FGF-4 in patients with Angina. J Am Coll Cardiol. 2007 Sep;50(11):1038–1046. 10.1016/j.jacc.2007.06.010.
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Zhu Y, Jiang H, et al. Intramyocardial injection of a fully synthetic hydrogel attenuates left ventricular remodeling post myocardial infarction. Biomaterials. 2019 Oct 1;217:119289.
   PubMed Web of Science ®Google Scholar
• Blackburn NJR, Sofrenovic T, Kuraitis D, et al. Timing underpins the benefits associated with injectable collagen biomaterial therapy for the treatment of myocardial infarction. Biomaterials. 2015 Jan 1;(39):182–192. https://doi.org/10.1016/j.biomaterials.2014.11.004
   Google Scholar
• Lister Z, Rayner KJ, Suuronen EJ. How biomaterials can influence various cell types in the repair and regeneration of the heart after myocardial infarction. Front Bioeng Biotechnol [Internet]. 2016 Jul 18 [ cited 2021 Mar 28];4. Available from:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948030.
   Google Scholar
• Barker TH. The role of ECM proteins and protein fragments in guiding cell behavior in regenerative medicine. Biomaterials. 2011 Jun 1;32(18):4211–4214.
   PubMed Web of Science ®Google Scholar
• Ahmed TA, Dare EV, Hincke M. Fibrin: a versatile scaffold for tissue engineering applications. Tissue Eng Part B Rev. 2008 Jun;14(2):199–215.
   PubMed Web of Science ®Google Scholar
• Christman KL, Fok HH, Sievers RE, et al. Fibrin glue alone and skeletal myoblasts in a fibrin scaffold preserve cardiac function after myocardial infarction. Tissue Eng. 2004 Mar;10(3–4):403–409.
   PubMedGoogle Scholar
• Shireman PK, Hampton B, Burgess WH, et al. Modulation of vascular cell growth kinetics by local cytokine delivery from fibrin glue suspensions. J Vasc Surg. 1999 May;29(5):852–861.
   PubMed Web of Science ®Google Scholar
• Zisch AH, Schenk U, Schense JC, et al. Covalently conjugated VEGF–fibrin matrices for endothelialization. J Control Release. 2001 May 14;72(1):101–113.
   PubMed Web of Science ®Google Scholar
• Jeon O, Ryu SH, Chung JH, et al. Control of basic fibroblast growth factor release from fibrin gel with heparin and concentrations of fibrinogen and thrombin. J Control Release. 2005 Jul 20;105(3):249–259.
   PubMed Web of Science ®Google Scholar
• Shi J, Fan C, Zhuang Y, et al. Heparan sulfate proteoglycan promotes fibroblast growth factor-2 function for ischemic heart repair. Biomater Sci. 2019 Nov 19;7(12):5438–5450.
   PubMed Web of Science ®Google Scholar
• Fan C, Shi J, Zhuang Y, et al. Myocardial-infarction-responsive smart hydrogels targeting matrix metalloproteinase for on-Demand growth factor delivery. Adv Mater. 2019;31(40):1902900.
   PubMed Web of Science ®Google Scholar
• An S, MJ P, Wang H, et al. Multi-phase catheter-injectable hydrogel enables dual-stage protein-engineered cytokine release to mitigate adverse left ventricular remodeling following myocardial infarction in a small animal model and a large animal model. Cytokine. 2020 Mar 1;127:154974.
   PubMed Web of Science ®Google Scholar
• Infanger DW, Lynch ME, Fischbach C. Engineered culture models for studies of tumor-microenvironment interactions. Annu Rev Biomed Eng. 2013 Jul 11;15(1):29–53.
   PubMedGoogle Scholar
• Wei Z, Volkova E, Blatchley MR, et al. Hydrogel vehicles for sequential delivery of protein drugs to promote vascular regeneration. Adv Drug Deliv Rev. 2019;149–150:95–106.
   PubMed Web of Science ®Google Scholar
• Zisch AH, Lutolf MP, Ehrbar M, et al. Cell-demanded release of VEGF from synthetic, biointeractive cell-ingrowth matrices for vascularized tissue growth. FASEB J. 2003;17(15):2260–2262.
   PubMed Web of Science ®Google Scholar
• Phelps EA, Landázuri N, Thulé PM, et al. Bioartificial matrices for therapeutic vascularization. Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3323–3328.
   PubMed Web of Science ®Google Scholar
• Saik JE, Gould DJ, Watkins EM, et al. Covalently immobilized platelet-derived growth factor-BB promotes angiogenesis in biomimetic poly(ethylene glycol) hydrogels. Acta Biomater. 2011 Jan;7(1):133–143.
   PubMed Web of Science ®Google Scholar
• Burdick JA, Prestwich GD. Hyaluronic acid hydrogels for biomedical applications. Adv Mater Deerfield Beach Fla. 2011 Mar 25;23(12):H41–56.
   PubMed Web of Science ®Google Scholar
• Peattie RA, Nayate AP, Firpo MA, et al. Stimulation of in vivo angiogenesis by cytokine-loaded hyaluronic acid hydrogel implants. Biomaterials. 2004 Jun 1;25(14):2789–2798.
   PubMed Web of Science ®Google Scholar
• Eiselt P, Yeh J, Latvala RK, et al. Porous carriers for biomedical applications based on alginate hydrogels. Biomaterials. 2000 Oct;21(19):1921–1927.
   PubMed Web of Science ®Google Scholar
• Spatially organized layers of cardiomyocytes on biodegradable polyurethane films for myocardial repair - McDevitt - 2003 - Journal of Biomedical Materials Research Part A - Wiley Online Library [Internet]. [ cited 2021 Mar 28]. Available from: https://onlinelibrary-wiley-com.eresources.mssm.edu/doi/full/10.1002/jbm.a.10504
   Google Scholar
• Yuan Z, Tsou Y-H, Zhang X-Q, et al. Injectable Citrate-based hydrogel as an angiogenic biomaterial improves cardiac repair after myocardial infarction. ACS Appl Mater Interfaces. 2019 Oct 23;11(42):38429–38439.
   PubMed Web of Science ®Google Scholar
• Biondi M, Ungaro F, Quaglia F, et al. Controlled drug delivery in tissue engineering. Adv Drug Deliv Rev. 2008 Jan 14;60(2):229–242.
   PubMed Web of Science ®Google Scholar
• Riley CM, Fuegy PW, Firpo MA, et al. Stimulation of in vivo angiogenesis using dual growth factor-loaded crosslinked glycosaminoglycan hydrogels. Biomaterials. 2006 Dec;27(35):5935–5943.
   PubMed Web of Science ®Google Scholar
• Peattie RA, Rieke ER, Hewett EM, et al. Dual growth factor-induced angiogenesis in vivo using hyaluronan hydrogel implants. Biomaterials. 2006 Mar 1;27(9):1868–1875.
   PubMed Web of Science ®Google Scholar
• Ruvinov E, Leor J, Cohen S. The promotion of myocardial repair by the sequential delivery of IGF-1 and HGF from an injectable alginate biomaterial in a model of acute myocardial infarction. Biomaterials. 2011 Jan;32(2):565–578.
   PubMed Web of Science ®Google Scholar
• Tengood JE, Ridenour R, Brodsky R, et al. Sequential delivery of basic fibroblast growth factor and platelet-derived growth factor for angiogenesis. Tissue Eng Part A. 2011 May;17(9–10):1181–1189.
   PubMed Web of Science ®Google Scholar
• Awada HK, Johnson NR, Wang Y. Sequential delivery of angiogenic growth factors improves revascularization and heart function after myocardial infarction. J Control Release Off J Control Release Soc. 2015 Jun 10;207:7–17.
   PubMed Web of Science ®Google Scholar
• Vasir JK, Tambwekar K, Garg S. Bioadhesive microspheres as a controlled drug delivery system. Int J Pharm. 2003 Apr 14;255(1):13–32.
   PubMedGoogle Scholar
• Lee J, Lee KY. Local and sustained vascular endothelial growth factor delivery for angiogenesis using an injectable system. Pharm Res. 2009 Jul;26(7):1739–1744.
   PubMed Web of Science ®Google Scholar
• Lee J, Bhang SH, Park H, et al. Active blood vessel formation in the ischemic hindlimb mouse model using a microsphere/hydrogel combination system. Pharm Res. 2010 May;27(5):767–774.
   PubMed Web of Science ®Google Scholar
• DeVolder R, Antoniadou E, Kong H. Enzymatically cross-linked injectable alginate-g-pyrrole hydrogels for neovascularization. J Control Release. 2013 Nov 28;172(1):30–37.
   PubMed Web of Science ®Google Scholar
• des Rieux A, Ucakar B, Mupendwa BPK, et al. 3D systems delivering VEGF to promote angiogenesis for tissue engineering. J Control Release. 2011 Mar 30;150(3):272–278.
   PubMed Web of Science ®Google Scholar
• Waters R, Alam P, Pacelli S, et al. Stem cell-inspired secretome-rich injectable hydrogel to repair injured cardiac tissue. Acta Biomater. 2018 Mar;15(69):95–106.
   Google Scholar
• Kantoff PW, Kohn DB, Mitsuya H, et al. Correction of adenosine deaminase deficiency in cultured human T and B cells by retrovirus-mediated gene transfer. Proc Natl Acad Sci U S A. 1986 Sep;83(17):6563–6567.
   PubMed Web of Science ®Google Scholar
• Ginn SL, Amaya AK, Alexander IE, et al. Gene therapy clinical trials worldwide to 2017: an update. J Gene Med. 2018;20(5):e3015.
   PubMed Web of Science ®Google Scholar
• Dunbar CE, High KA, Joung JK, et al. Gene therapy comes of age. Science. 2018 Jan 12;359(6372):eaan4672.
   PubMed Web of Science ®Google Scholar
• Kaminsky SM, Rosengart TK, Rosenberg J, et al. Gene therapy to stimulate angiogenesis to treat diffuse coronary artery disease. Hum Gene Ther. 2013 Nov;24(11):948–963.
   PubMed Web of Science ®Google Scholar
• Ylä-Herttuala S, Bridges C, Katz MG, et al. Angiogenic gene therapy in cardiovascular diseases: dream or vision? Eur Heart J. 2017 Jan 10: ehw547. https://doi.org/10.1093/eurheartj/ehw547
   Google Scholar
• Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat Rev Genet. 2003 May;4(5):346–358.
   PubMed Web of Science ®Google Scholar
• Anson DS. The use of retroviral vectors for gene therapy-what are the risks? A review of retroviral pathogenesis and its relevance to retroviral vector-mediated gene delivery. Genet Vaccines Ther. 2004Aug13;2(1):9.
   PubMedGoogle Scholar
• Gyöngyösi M, Khorsand A, Zamini S, et al. NOGA-guided analysis of regional myocardial perfusion abnormalities treated with intramyocardial injections of plasmid encoding vascular endothelial growth factor A-165 in patients with chronic myocardial ischemia: subanalysis of the EUROINJECT-ONE multicenter double-blind randomized study. Circulation. 2005 Aug 30;112(9 Suppl):I157–165.
   PubMed Web of Science ®Google Scholar
• Crystal RG, Harvey B-G, Wisnivesky JP, et al. Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. Hum Gene Ther. 2002 Jan 1;13(1):65–100.
   PubMed Web of Science ®Google Scholar
• Chung ES, Miller L, Patel AN, et al. Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial. Eur Heart J. 2015 Sep 1;36(33):2228–2238.
   PubMed Web of Science ®Google Scholar
• Greenberg B, Butler J, Felker GM, et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet Lond Engl. 2016 Mar 19;387(10024):1178–1186.
   PubMed Web of Science ®Google Scholar
• Halonen PJ, Nurro J, Kuivanen A, et al. Current gene therapy trials for vascular diseases. Expert Opin Biol Ther. 2014 Mar;14(3):327–336.
   PubMed Web of Science ®Google Scholar
• Kilian EG, Sadoni S, Vicol C, et al. Myocardial transfection of hypoxia inducible factor-1alpha via an adenoviral vector during coronary artery bypass grafting. - A multicenter phase I and safety study -. Circ J Off J Jpn Circ Soc. 2010 May;74(5):916–924.
   PubMed Web of Science ®Google Scholar
• Rischpler C, Nekolla S, Schwaiger M. PET and SPECT in heart failure. Curr Cardiol Rep. 2013 Mar;15(3):337.
   PubMed Web of Science ®Google Scholar
• Kastrup J, Jørgensen E, Rück A, et al. Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the euroinject one trial. J Am Coll Cardiol. 2005 Apr 5;45(7):982–988.
   PubMed Web of Science ®Google Scholar
• Kukuła K, Chojnowska L, Dąbrowski M, et al. Intramyocardial plasmid-encoding human vascular endothelial growth factor A165/basic fibroblast growth factor therapy using percutaneous transcatheter approach in patients with refractory coronary artery disease (VIF-CAD). Am Heart J. 2011 Mar;161(3):581–589.
   PubMed Web of Science ®Google Scholar
• Hedman M, Muona K, Hedman A, et al. Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer. Gene Ther. 2009 May;16(5):629–634.
   PubMed Web of Science ®Google Scholar
• Hedman M, Hartikainen J, Ylä-Herttuala S. Progress and prospects: hurdles to cardiovascular gene therapy clinical trials. Gene Ther. 2011 Aug;18(8):743–749.
   PubMed Web of Science ®Google Scholar
• Favaloro L, Diez M, Mendiz O, et al. High-dose plasmid-mediated VEGF gene transfer is safe in patients with severe ischemic heart disease (genesis-I). A phase I, open-label, two-year follow-up trial: VEGF gene transfer in myocardial Ischemia. Catheter Cardiovasc Interv. 2013 Nov 15;82(6):899–906.
   PubMed Web of Science ®Google Scholar
• Kastrup J, Jørgensen E, Fuchs S, et al. A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial. EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol. 2011 Feb;6(7):813–818.
   Google Scholar
• Hartikainen J, Hassinen I, Hedman A, et al. Adenoviral intramyocardial VEGF-DΔNΔC gene transfer increases myocardial perfusion reserve in refractory angina patients: a phase I/IIa study with 1-year follow-up. Eur Heart J. 2017 Sep 1;38(33):2547–2555.
   PubMed Web of Science ®Google Scholar
• Kaski JC, Consuegra-Sanchez L. Evaluation of ASPIRE trial: a Phase III pivotal registration trial, using intracoronary administration of Generx (Ad5FGF4) to treat patients with recurrent angina pectoris. Expert Opin Biol Ther. 2013 Dec;13(12):1749–1753.
   PubMed Web of Science ®Google Scholar
• Hou L, Kim JJ, Woo YJ, et al. Stem cell-based therapies to promote angiogenesis in ischemic cardiovascular disease. Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H455–465.
   PubMed Web of Science ®Google Scholar
• Perin EC, Willerson JT, Pepine CJ, et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN Trial. JAMA. 2012Apr25; cited 2021 Mar 6];307(16). Available from: http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2012.418.
   PubMed Web of Science ®Google Scholar
• Traverse JH, Henry TD, Ellis SG, et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA. 2011 Nov 16;306(19):2110–2119.
   PubMed Web of Science ®Google Scholar
• Wollert KC, Meyer GP, Lotz J, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet Lond Engl. 2004 Jul 10;364(9429):141–148.
   PubMed Web of Science ®Google Scholar
• Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the Poseidon randomized trial. JAMA. 2012 Dec 12;308(22):2369.
   PubMed Web of Science ®Google Scholar
• Losordo DW, Henry TD, Davidson C, et al. Intramyocardial, autologous CD34+ cell therapy for refractory angina. Circ Res. 2011 Aug 5;109(4):428–436.
   PubMed Web of Science ®Google Scholar
• Park S-J, Kim RY, Park B-W, et al. Dual stem cell therapy synergistically improves cardiac function and vascular regeneration following myocardial infarction. Nat Commun. 2019 Dec;10(1):3123.
   PubMedGoogle Scholar
• Cambria E, Pasqualini FS, Wolint P, et al. Translational cardiac stem cell therapy: advancing from first-generation to next-generation cell types. Npj Regen Med. 2017 Dec;2(1):17.
   PubMedGoogle Scholar
• Bian X, Ma K, Zhang C, et al. Therapeutic angiogenesis using stem cell-derived extracellular vesicles: an emerging approach for treatment of ischemic diseases. Stem Cell Res Ther. 2019 Dec;10(1):158.
   PubMedGoogle Scholar
• Makridakis M, Roubelakis MG, Vlahou A. Stem cells: insights into the secretome. Biochim Biophys Acta BBA - Proteins Proteomics. 2013 Nov;1834(11):2380–2384.
   PubMed Web of Science ®Google Scholar
• Nasser M, Wu Y, Danaoui Y, et al. Engineering microenvironments towards harnessing pro-angiogenic potential of mesenchymal stem cells. Mater Sci Eng C Mater Biol Appl. 2019 Sep;102:75–84.
   PubMed Web of Science ®Google Scholar
• Muralidharan-Chari V, Clancy JW, Sedgwick A, et al. Microvesicles: mediators of extracellular communication during cancer progression. J Cell Sci. 2010 May 15;123(10):1603–1611.
   PubMed Web of Science ®Google Scholar
• Ren S, Chen J, Duscher D, et al. Microvesicles from human adipose stem cells promote wound healing by optimizing cellular functions via AKT and ERK signaling pathways. Stem Cell Res Ther. 2019 Dec;10(1):47.
   PubMed Web of Science ®Google Scholar
• Zhang B, Wu X, Zhang X, et al. Human umbilical cord mesenchymal stem cell exosomes enhance angiogenesis through the Wnt4/β-Catenin pathway: hucMSC Exosomal Wnt4 promotes angiogenesis. STEM CELLS Transl Med. 2015 May;4(5):513–522.
   PubMed Web of Science ®Google Scholar
• Namazi H, Mohit E, Namazi I, et al. Exosomes secreted by hypoxic cardiosphere-derived cells enhance tube formation and increase pro-angiogenic miRNA. J Cell Biochem. 2018 May;119(5):4150–4160.
   PubMed Web of Science ®Google Scholar
• Potz BA, Parulkar AB, Abid RM, et al. Novel molecular targets for coronary angiogenesis and ischemic heart disease. Coron Artery Dis. 2017 Nov;28(7):605–613.
   PubMed Web of Science ®Google Scholar
• Potz BA, Sabe AA, Elmadhun NY, et al. Calpain inhibition modulates glycogen synthase kinase 3β pathways in ischemic myocardium: a proteomic and mechanistic analysis. J Thorac Cardiovasc Surg. 2017 Feb;153(2):342–357.
   PubMed Web of Science ®Google Scholar
• Potz BA, Sabe AA, Elmadhun NY, et al. Glycogen synthase kinase 3β inhibition improves myocardial angiogenesis and perfusion in a swine model of metabolic syndrome. J Am Heart Assoc. 2016 Jul 12;5(7). https://doi.org/10.1161/JAHA.116.003694.
   Google Scholar
• Matyal R, Chu L, Mahmood F, et al. Neuropeptide Y improves myocardial perfusion and function in a swine model of hypercholesterolemia and chronic myocardial ischemia. J Mol Cell Cardiol. 2012 Dec;53(6):891–898.
   PubMed Web of Science ®Google Scholar
• Meier P, Gloekler S, de Marchi SF, et al. Myocardial salvage through coronary collateral growth by granulocyte colony-stimulating factor in chronic coronary artery disease: a controlled randomized trial. Circulation. 2009 Oct 6;120(14):1355–1363.
   PubMed Web of Science ®Google Scholar
• Seiler C, Pohl T, Wustmann K, et al. Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Circulation. 2001 Oct 23;104(17):2012–2017.
   PubMed Web of Science ®Google Scholar
• Freedman SB, Isner JM. Therapeutic angiogenesis for coronary artery disease. Ann Intern Med. 2002 Jan 1;136(1):54.
   PubMed Web of Science ®Google Scholar
• Briones E, Lacalle JR, Marin-Leon I, et al. Transmyocardial laser revascularization versus medical therapy for refractory angina. Cochrane Database Syst Rev. 2015 Feb;27(2):CD003712.
   Google Scholar
• Moccia F, Antognazza MR, Lodola F. Towards novel geneless approaches for therapeutic angiogenesis. Front Physiol. 2021 Jan;20(11):616189.
   Google Scholar
• Lodola F, Rosti V, Tullii G, et al. Conjugated polymers optically regulate the fate of endothelial colony-forming cells. Sci Adv. 2019 Sep;5(9):eaav4620.
   PubMed Web of Science ®Google Scholar
• Hagen MW, Hinds MT. The effects of topographic micropatterning on endothelial colony-forming cells. Tissue Eng Part A. 2021 Feb 1;27(3–4):270–281.
   PubMed Web of Science ®Google Scholar
• Simons M, Ware JA. Therapeutic angiogenesis in cardiovascular disease. Nat Rev Drug Discov. 2003 Nov;2(11):863–872.
   PubMed Web of Science ®Google Scholar
• Simons M, Bonow RO, Chronos NA, et al. Clinical trials in coronary angiogenesis: issues, problems, consensus: an expert panel summary. Circulation. 2000 Sep 12;102(11):E73–86.
   PubMed Web of Science ®Google Scholar
• Spertus JA, Winder JA, Dewhurst TA, et al. Development and evaluation of the Seattle angina questionnaire: a new functional status measure for coronary artery disease. J Am Coll Cardiol. 1995 Feb;25(2):333–341.
   PubMed Web of Science ®Google Scholar
• Niu G, Chen X. PET Imaging of Angiogenesis. PET Clin. 2009 Jan 1;4(1):17–38.
   PubMedGoogle Scholar
• Marlies O, Kim D, Allard W, et al. Molecular magnetic resonance imaging of myocardial angiogenesis after acute myocardial infarction. Circulation. 2010 Feb 16;121(6):775–783.
   PubMed Web of Science ®Google Scholar
• Wykrzykowska JJ, Henry TD, Lesser JR, et al. Imaging myocardial angiogenesis. Nat Rev Cardiol. 2009 Oct;6(10):648–658.
   PubMed Web of Science ®Google Scholar
• Laham RJ, Rezaee M, Post M, et al. Intracoronary and intravenous administration of basic fibroblast growth factor: myocardial and tissue distribution. Drug Metab Dispos Biol Fate Chem. 1999 Jul;27(7):821–826.
   PubMed Web of Science ®Google Scholar
• Post MJ, Laham R, Sellke FW, et al. Therapeutic angiogenesis in cardiology using protein formulations. Cardiovasc Res. 2001 Feb 16;49(3):522–531.
   PubMed Web of Science ®Google Scholar
• Peirce SM, Price RJ, Skalak TC. Spatial and temporal control of angiogenesis and arterialization using focal applications of VEGF164 and Ang-1*. Am J Physiol-Heart Circ Physiol. 2004 Mar 1;286(3):H918–25.
   PubMed Web of Science ®Google Scholar
• Lee DJ, Rocker AJ, Bardill JR, et al. A sulfonated reversible thermal gel for the spatiotemporal control of VEGF delivery to promote therapeutic angiogenesis. J Biomed Mater Res A. 2018;106(12):3053–3064.
   PubMed Web of Science ®Google Scholar
• González-Pérez F, Ibáñez-Fonseca A, Alonso M, et al. Combining tunable proteolytic sequences and a VEGF-mimetic peptide for the spatiotemporal control of angiogenesis within Elastin-Like recombinamer scaffolds. Acta Biomater. 2021 Aug;130:149–160.
   PubMed Web of Science ®Google Scholar
• Robich Michael P, Osipov Robert M, Reza N, et al. Resveratrol improves myocardial perfusion in a swine model of hypercholesterolemia and chronic myocardial Ischemia. Circulation. 2010 Sep 14;122(11_suppl_1):S142–9.
   PubMed Web of Science ®Google Scholar
• Greenberg JI, Shields DJ, Barillas SG, et al. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature. 2008 Dec;456(7223):809–813.
   PubMed Web of Science ®Google Scholar
• Frontini MJ, Nong Z, Gros R, et al. Fibroblast growth factor 9 delivery during angiogenesis produces durable, vasoresponsive microvessels wrapped by smooth muscle cells. Nat Biotechnol. 2011 May;29(5):421–427.
   PubMed Web of Science ®Google Scholar
• Epstein Stephen E, Ran K, Shmuel F, et al. Angiogenesis Therapy. Circulation. 2001 Jul 3;104(1):115–119.
   PubMedGoogle Scholar
• Flugelman MY, Virmani R, Correa R, et al. Smooth muscle cell abundance and fibroblast growth factors in coronary lesions of patients with nonfatal unstable angina. A clue to the mechanism of transformation from the stable to the unstable clinical state. Circulation. 1993 Dec;88(6):2493–2500.
   PubMed Web of Science ®Google Scholar
• Inoue M, Itoh H, Ueda M, et al. Vascular endothelial growth factor (VEGF) expression in human coronary atherosclerotic lesions: possible pathophysiological significance of VEGF in progression of atherosclerosis. Circulation. 1998 Nov 17;98(20):2108–2116.
   PubMed Web of Science ®Google Scholar
• Tammela T, Enholm B, Alitalo K, et al. The biology of vascular endothelial growth factors. Cardiovasc Res. 2005 Feb 15;65(3):550–563.
   PubMed Web of Science ®Google Scholar
• Roy H, Bhardwaj S, Ylä-Herttuala S. Biology of vascular endothelial growth factors. FEBS Lett. 2006 May 22;580(12):2879–2887.
   PubMed Web of Science ®Google Scholar
• Ylä-Herttuala S, Rissanen TT, Vajanto I, et al. Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol. 2007 Mar 13;49(10):1015–1026.
   PubMed Web of Science ®Google Scholar